Sommetrics Presents Update on Pivotal SUPRA Sleep Apnea Trial at International Sleep and Breathing Conference

SAN DIEGO–(BUSINESS WIRE)–Sommetrics, a private company developing products and services to improve sleep health, today announced presentation of an interim update on its pivotal SUPRA study (Study Using Negative Pressure to Reduce Apnea) at the tri-annual, XVII International Symposium on Sleep and Breathing in Auckland, New Zealand. The presenter was Dr. Kingman Strohl, Program Director, Sleep Medicine, University Hospital, Cleveland, and Professor of Medicine, Case School of Medicine; he is the global Principal Investigator for the study. The SUPRA trial is intended to assess the treatment benefit and safety of Sommetrics� flagship aerSleep® II product in those with moderate and severe obstructive sleep apnea who are unable to use continuous positive airway pressure (CPAP) therapy. The self-contained and non-invasive aerSleep II device externally applies mild vacuum to the neck to expand the upper airway, eliminating the need for a face mask or tether of any kind.

Dr. Strohl’s interim update highlights the initial treatment benefits for subjects who successfully acclimated to wearing the device and exhibited a response to the single vacuum pressure being tested. In these 27 subjects, the apnea hypopnea index (the standard measure of disease severity) was reduced from 27.5 ± 10.5 (mean ± standard deviation) at baseline when the aerSleep II device was not being worn to 8.7 ± 5.7 on treatment. Nine of 10 subjects who have completed 6 months of home use exhibited further reduction in AHI to 6.9 ± 5.5. To date, side effects have been mostly mild, self-limited skin irritation on the neck. Importantly, aerSleep II appears to be well tolerated as evidenced by standard measures of treatment compliance in those who have completed 6 months of home use.

Dr. Strohl had these comments:

“There is strong optimism at the SUPRA study sites and enthusiasm among study participants about aerSleep II. To date, we are pleased with the excellent safety profile of the device and its utility as a new class for OSA therapy. We look forward to reporting on aerSleep’s effectiveness when the study is completed.”

SUPRA builds upon favorable clinical study results seen with a first generation aerSleep® I device, which demonstrated a reduction in apnea and a favorable safety profile in multiple earlier studies conducted in the U.S. and Canada. These studies were the basis of a Health Canada Medical Device License for aerSleep® I, and the Breakthrough Device designation by the FDA for the second generation aerSleep® II product. More information about the SUPRA trial may be found at clinicaltrials.gov (NCT04861038). Enrollment in the SUPRA trial is currently ongoing. aerSleep® II is an investigational device and has not been cleared or approved for sale in the US or any jurisdiction.

About Sommetrics

Sommetrics is a privately funded company located in San Diego, California. It is focused on improving sleep quality by providing products and services that deal with disorders of the upper airway such as obstructive sleep apnea (OSA) and snoring. For more information, visit www.sommetrics.com.

Contacts

Cory Lancaster

SVP Finance/Investor Relations

760-295-5620

info@sommetrics.com
www.sommetrics.com